HIV/AIDSResearch Achievements - Research Achievement - About Us

Research Achievement

Our R&D achievements
have been repeatedly
recognized by global
academic authorities.

When allergies keep people from sleeping and viral infections remain without a cure, we aspire to be the starting point of change.

From the laboratory to the global stage, our innovative monoclonal antibodies have been repeatedly recognized by leading academic authorities worldwide. Our research is frequently published in top-tier journals such as The New England Journal of Medicine, The Lancet, and Nature, demonstrating our core competitiveness and international influence in the field of monoclonal antibodies. We firmly believe that these science-driven innovations will bring meaningful improvements to patients around the world and mark a new chapter in the history of human medicine.

HIV/AIDS
Research Achievements

UB-421

The latest research findings were published on January 3, 2025, in a high-impact Nature series medical journal, demonstrating the promising therapeutic efficacy of UB-421 for patients with multidrug-resistant HIV.

The Phase II clinical trial of UB-421 achieved outstanding results, earning publication in the prestigious New England Journal of Medicine and gaining significant international recognition.

The collaborative research on UB-421 with partners in the United States has yielded remarkable results. Its therapeutic potential in treating drug-resistant HIV has attracted significant attention from the scientific community, and in June 2024, it was once again published in the prestigious Lancet series.

01 / 03
Chronic Spontaneous Urticaria (CSU)
Research Achievements

UB-221

UB-221 has also attracted significant attention from the scientific community. Its research findings were published in 2022 in the prestigious Journal of Clinical Investigation (JCI), a highly respected journal in the field of medicine.

01 / 03
Recurrent Genital Herpes
Research Achievements

UB-621

Although UB-621 has only completed animal studies, it has nevertheless drawn significant attention from the scientific community. Related research data were published in 2022 in two important journals — Journal of Experimental Medicine and Frontiers in Immunology.

01 / 03